Targeting minimal residual disease: a path to cure?
Marlise R. Luskin(Dana-Farber Cancer Institute), David M. Weinstock(Broad Institute), Scott R. Manalis(Massachusetts Institute of Technology), Mark A. Murakami(Harvard University)
Cited by 164
Related Papers
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
|The Lancet Oncology|2015|613
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
|Cell|2021|586
The promise of organ and tissue preservation to transform medicine
|Nature Biotechnology|2017|530